Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples.

Bournet B, Pointreau A, Souque A, Oumouhou N, Muscari F, Lepage B, Senesse P, Barthet M, Lesavre N, Hammel P, Levy P, Ruszniewski P, Cordelier P, Buscail L.

Pancreatology. 2012 Jan-Feb;12(1):27-34. doi: 10.1016/j.pan.2011.12.003. Epub 2011 Dec 17.

PMID:
22487470
2.

MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.

du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P.

Clin Chem. 2010 Apr;56(4):603-12. doi: 10.1373/clinchem.2009.137364. Epub 2010 Jan 21.

3.

Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.

Bournet B, Souque A, Senesse P, Assenat E, Barthet M, Lesavre N, Aubert A, O'Toole D, Hammel P, Levy P, Ruszniewski P, Bouisson M, Escourrou J, Cordelier P, Buscail L.

Endoscopy. 2009 Jun;41(6):552-7. doi: 10.1055/s-0029-1214717. Epub 2009 Jun 16.

PMID:
19533561
4.

let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.

Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, Buscail L, Cordelier P.

Hum Gene Ther. 2009 Aug;20(8):831-44. doi: 10.1089/hum.2008.134.

PMID:
19323605
5.

Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications.

Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P, Buscail L.

Endocrinology. 2008 Jun;149(6):3137-47. doi: 10.1210/en.2007-1525. Epub 2008 Mar 6.

PMID:
18325993
6.

Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.

Vernejoul F, Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, Tiraby G.

Mol Ther. 2006 Dec;14(6):758-67. Epub 2006 Sep 25.

7.

Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.

Péron JM, Bureau C, Gourdy P, Lulka H, Souque A, Calippe B, Selves J, Al Saati T, Bernad J, Cordelier P, Couderc B, Pradayrol L, Pipy B, Buscail L, Vinel JP.

Gut. 2007 Jan;56(1):107-14. Epub 2006 Aug 4.

8.

Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells.

Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, Susini C, Buscail L, Cordelier P.

Hum Gene Ther. 2005 Oct;16(10):1175-93.

PMID:
16218779
9.

Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.

Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, Rafestin-Oblin ME.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):181-8.

PMID:
15134816
10.

Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12.

Peron JM, Couderc B, Rochaix P, Douin-Echinard V, Asnacios A, Souque A, Voigt JJ, Buscail L, Vinel JP, Favre G.

J Gastroenterol Hepatol. 2004 Apr;19(4):388-96.

PMID:
15012775
11.

The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related.

Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A.

Endocrinology. 2003 Feb;144(2):528-33.

PMID:
12538613
12.

11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.

Rafestin-Oblin ME, Fagart J, Souque A, Seguin C, Bens M, Vandewalle A.

Mol Pharmacol. 2002 Dec;62(6):1306-13.

PMID:
12435797
13.

A new human MR splice variant is a ligand-independent transactivator modulating corticosteroid action.

Zennaro MC, Souque A, Viengchareun S, Poisson E, Lombès M.

Mol Endocrinol. 2001 Sep;15(9):1586-98.

PMID:
11518808
14.

A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones.

Auzou G, Fagart J, Souque A, Hellal-Lévy C, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Pharmacol. 2000 Oct;58(4):684-91.

PMID:
10999937
15.

Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor.

Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Endocrinol. 2000 Aug;14(8):1210-21.

PMID:
10935545
16.

Mechanistic aspects of mineralocorticoid receptor activation.

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

Kidney Int. 2000 Apr;57(4):1250-5. Review.

17.

[Corticosteroid hormones: mechanisms involved in the recognition of aldosterone by mineralocorticoid receptors].

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

J Soc Biol. 1999;193(4-5):355-60. Review. French.

PMID:
10689617
18.

Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.

Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M.

FEBS Lett. 1999 Dec 24;464(1-2):9-13.

19.

Photoaffinity labelling of the human mineralocorticoid receptor with steroids having a reactive group at position 3, 18 or 21.

Fagart J, Couette B, Souque A, Davioud E, Marquet A, Rafestin-Oblin ME.

Biochim Biophys Acta. 1998 Oct 14;1388(1):35-44.

PMID:
9774704
20.

Antagonism in the human mineralocorticoid receptor.

Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin ME.

EMBO J. 1998 Jun 15;17(12):3317-25.

21.

New steroidal diazo ketones as potential photoaffinity labeling reagents for the mineralocorticoid receptor: synthesis and biological activities.

Davioud E, Fagart J, Souque A, Rafestin-Oblin ME, Marquet A.

J Med Chem. 1996 Jul 5;39(14):2860-4.

PMID:
8709117
22.

Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.

Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, Rafestin-Oblin ME.

Biochem J. 1996 Apr 15;315 ( Pt 2):421-7.

23.

Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor.

Souque A, Fagart J, Couette B, Rafestin-Oblin ME.

J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):315-21.

PMID:
8639467
24.

The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.

Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, Rafestin-Oblin ME.

Endocrinology. 1995 Dec;136(12):5651-8.

PMID:
7588320
25.

The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.

Lombes M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME.

Endocrinology. 1994 Sep;135(3):834-40.

PMID:
8070376
26.
27.

Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Gros C, Noël N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J.

Proc Natl Acad Sci U S A. 1991 May 15;88(10):4210-4.

28.
29.

Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans.

Lecomte JM, Baumer P, Lim C, Duchier J, Cournot A, Dussaule JC, Ardaillou R, Gros C, Chaignon B, Souque A, et al.

Eur J Pharmacol. 1990 Apr 10;179(1-2):65-73.

PMID:
2163851
30.

Inactivation of atrial natriuretic factor in mice in vivo: crucial role of enkephalinase (EC 3.4.24.11).

Gros C, Souque A, Schwartz JC.

Eur J Pharmacol. 1990 Apr 10;179(1-2):45-56.

PMID:
2142086
31.

Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Gros C, Souque A, Schwartz JC, Duchier J, Cournot A, Baumer P, Lecomte JM.

Proc Natl Acad Sci U S A. 1989 Oct;86(19):7580-4.

32.

Lymphoid stromal reaction in gastrointestinal lymphomas: immunohistochemical study of 14 cases.

Jarry A, Brousse N, Souque A, Barge J, Molas G, Potet F.

J Clin Pathol. 1987 Jul;40(7):760-5.

33.

Reversible inhibition of the in vitro coagulation of human plasma by lectins.

Freyssinet JM, Thevenon D, Souque A, Suscillon M.

Thromb Haemost. 1982 Oct 29;48(2):120-4.

PMID:
6897462

Supplemental Content

Loading ...
Support Center